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ABSTRACT 
OBJECTIVE: The purpose of this EBM review is to determine, “Does Mesalazine improve the 
symptoms of patients with irritable bowel syndrome (IBS)?”. 
STUDY DESIGN: Review of three English language primary studies, published between 2011 
and 2016. 
DATA SOURCES: Three randomized controlled trials (RCTs) were found through the Cochrane 
Library, Embase, and PubMed. These studies analyzed the effectiveness of Mesalazine in 
treating the symptoms of patients with IBS. 
OUTCOMES MEASURED: The outcomes measured included relief of abdominal pain (primary 
outcome) and abdominal pain intensity. The outcomes were measured by a binary scale (“yes” or 
“no” or relief of pain, pain severity scale rated on a scale of 1-10, and an abdominal pain 
score/scale of 0-10. P-values were used to assess the significance of these outcomes in two 
studies, and NNT (number needed to treat), RBI (relative benefit increase), and ABI (absolute 
benefit increase) were used to assess the significance of these outcomes in one study. 
 
RESULTS: The results from the studies show conflicting evidence, as two studies showed no 
statistically significant difference in the relief of abdominal pain/pain intensity between 
Mesalazine and Placebo treatment. However, one study did support the question that Mesalazine 
had a greater effect on treating abdominal pain than the standard treatment for IBS.  
 
CONCLUSION: Based upon the evidence and results shown in the three studies reviewed, the 
use of Mesalazine in treating the primary symptom of IBS, abdominal pain, cannot be justified as 
a statistically significant treatment. Barbara and Lam both showed that Mesalazine did not have a 
statistically significant effect on the relief of abdominal pain or lowered abdominal pain intensity 
post-treatment, while Dorofeyev did show that Mesalazine was superior to standard therapy 
without Mesalazine. Thus, further investigation should be carried out to determine if Mesalazine 
is truly effective at improving the main symptom of abdominal pain in IBS patients. 
 
KEY WORDS: Irritable Bowel Syndrome, Mesalazine
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INTRODUCTION 
Irritable Bowel Syndrome, or IBS, is a condition of the gastrointestinal tract that is 
characterized primarily by “chronic abdominal pain and altered bowel habits”.1 This topic of 
medicine is relevant to the practice of Physician Assistants due to the high prevalence of the 
disease. In fact, it is estimated that 10-20% of the North American population is affected by IBS, 
so it is an extremely relevant condition to be familiar with as a practicing PA.1 In addition to the 
high percentage of the North American population affected by IBS, “25-50% of all 
gastroenterologist referrals” involve IBS.4  
In addition to the high prevalence of the disease, there are significant direct medical costs 
that can be attributed to IBS. In the United States, it is estimated to be around $1.6–$10.5 billion 
per year.5,6,7 IBS also accounts for an astounding number of healthcare visits, where the disease 
accounted for 1.6 million ambulatory care visits in 2009 and 280,000 hospitalizations in 2010.8,9 
While the exact pathophysiology of IBS is unknown, there are several proposed factors 
that may play into the mechanisms of the condition, such as “altered gastrointestinal motility, 
visceral hypersensitivity, post infectious reactivity, alteration in fecal micro flora, bacterial 
overgrowth, food sensitivity, carbohydrate malabsorption, and intestinal inflammation”.12 
In addition to the multiple proposed etiologies of the disease, there are a myriad of 
different methods used to treat IBS. They initially include reassurance, education, diet 
modifications, and increased physical activity.12 There are other pharmacologic agents, such as 
laxatives for constipation symptoms, anti-diarrheal agents for diarrhea symptoms, bile acid 
sequestrants for diarrhea symptoms, and antispasmodics such as Dicyclomine.12,14 In addition, 
antidepressants, such as tricyclic antidepressants, have shown positive analgesic effects in 
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patients with IBS.13 In patients that have not responded to the above treatments, a short trial of 
antibiotics, such as Rifaximin, may be prescribed.15 
While these treatments have the potential to relieve common symptoms of IBS and help 
patients to live a symptom-free life, each patient responds to treatments differently, and some 
patients may not respond completely to multiple different treatments. Therefore, different 
treatment methods have been sought out by researchers. One such treatment method is 
Mesalazine, which is widely known to be a common treatment for IBD patients. Because one of 
the proposed factors contributing to the pathophysiology of IBS is intestinal inflammation, it has 
been proposed by some researchers that anti-inflammatory medications, such as Mesalazine, may 
prove to be effective.3 
OBJECTIVE 
The purpose of this EBM review is to determine “Does Mesalazine improve the 
symptoms of patients with irritable bowel syndrome (IBS)?”. 
METHODS 
There were several criterion used in the selection of studies. The populations in these 
studies included both male and female patients that met the Rome III criteria for an IBS 
diagnosis,11 and that were greater than eighteen years of age. Each of the studies used in this 
review used Mesalazine as an intervention for measuring patients’ IBS symptoms resolving with 
treatment. These interventions included 800mg PO 3 x daily for 12 weeks, followed for an 
additional 12 weeks,1 500 mg Mesalazine 4 x daily for 28 days,2 and 2 grams Mesalazine PO 
twice daily for 3 months.3 These interventions were compared to placebo PO 3 x daily for 12 
weeks,1 standard therapy without Mesalazine for 28 days,2 and 2 g placebo PO once daily for one 
week, and if tolerated, then 2 g twice a day for 11 weeks,3 respectively. The primary outcome 
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that is being addressed is the relief of the IBS symptom of abdominal pain. This outcome was 
measured by a binary scale,1 and various pain severity score scales.2,3 The types of studies 
included in this review included a phase III, Multicenter, Tertiary setting, Parallel-Arm, 
Randomized, Double-Blind, Placebo-Controlled Trial,1 a controlled, randomized, blind clinical 
trial,2 and a multicenter, two-arm, parallel-group, double-blind, randomized placebo-controlled 
trial.3 
The author used the keywords “Mesalazine”, “Mesalamine”, “Irritable Bowel 
Syndrome”, and “IBS” to carry out a detailed search of different studies. The detailed search 
included searching through the Cochrane Library, Embase, and PubMed. All articles that were 
selected for use in this review were based on relevance and that the outcomes of the studies were 
patient-oriented outcomes (POEMs). All articles selected were published in English, and all 
articles selected were published in peer-reviewed journals. Inclusion criteria included studies that 
were RCTs published after 2001, and exclusion criteria included studies with patients under the 
age of 18 or studies that included patients that did not fit the criteria of an IBS diagnosis. The 
statistics reported in these articles included p-values, where a p-value < 0.05 was considered 
statistically significant, and one article included information to calculate the number needed to 
treat (NNT), relative benefit increase (RBI), and absolute benefit increase (ABI). A detailed 
listing of the characteristics of the included studies is listed in Table 1 below. 
Table 1 - Demographics & Characteristics of Included Studies 
Study Type # Pts Age 
(yrs) 
Inclusion Criteria Exclusion Criteria W/D Interventions 
Barbar
a 
(2016)
1 
Parallel-
Arm, 
Randomi
zed, 
Double-
Blind, 
Placebo-
180 18 -
65 
Positive diagnosis of 
all IBS subtypes and 
negative colonoscopy 
or barium enema 
examination within the 
previous 5 years or 
negative relevant 
Pts. that were 
pregnant, currently 
used NSAIDs, 
steroids, or mast cell 
stabilizers, current 
use of antibiotics, 
treatment with 
lactulose, pts. with a 
50 Mesalazine, 
800 mg, 3 x 
daily for 12 
weeks and 
followed for an 
additional 12 
weeks 
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Controlle
d Trial 
additional screening or 
consultation. 
history of abdominal 
surgery, history of 
IBD or celiac 
disease, pts. with 
asthma, or patients 
with psychiatric 
disorders. 
Dorofe
yev 
(2011)
2 
Controlle
d, 
randomiz
ed, blind 
clinical 
trial 
360 18 -
65 
Diagnosis of IBS 
according to Rome III 
criteria, absence of 
any bowel infection, 
or post-infectious IBS. 
Pts. with specific 
alarm symptoms 
such as first 
symptoms ≥ 50 
years, loss of weight, 
blood in stool, fever, 
or cancer anamnesis 
in relatives 
0 500 mg 
Mesalazine 4 x 
daily for 28 
days 
Lam 
(2016)
3 
Multicen
ter, two-
arm, 
parallel-
group, 
double-
blind, 
randomiz
ed 
placebo-
controlle
d trial 
136 18 -
75 
Diagnosis of IBS- D 
according to modified 
Rome III criteria, 
normal colonoscopy, 
normal blood count, 
serum calcium and 
albumin, C-reactive 
protein and negative 
test for Celiac and 
lactose intolerance, 
among others listed in 
article. 
Pregnancy, prior 
history of major 
abdominal surgery, 
liver or kidney 
impairment or 
chronic ingestion of 
any anti-
inflammatory drugs 
or medications that 
could affect drug 
motility.  
16 2 grams 
Mesalazine PO 
twice daily for 
3 months 
 
OUTCOMES MEASURED 
The primary outcome that is being addressed in this review the relief of the symptom of 
abdominal pain, which is considered a POEM. This outcome should help to answer the question 
“Does Mesalazine improve the symptoms of patients with irritable bowel syndrome (IBS)?”, as 
abdominal pain is a key feature of the disease. With the first article, authored by Barbara et al, 
the primary efficacy endpoint was satisfactory relief of abdominal pain/discomfort for at least 
half of the weeks of the treatment period.1 The primary endpoint was assessed using a binary 
scale based on the patients’ answers to the following weekly question: “Did you have 
satisfactory relief of your abdominal discomfort or pain during the last week?”1. The patients 
were classified as responders if they reported an affirmative answer in at least 50% of weeks 
over a 3-month treatment period (50% rule).1 
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The primary outcome that Dorofeyev et al measured was the parameter of pain intensity.2 
Before and after treatment, patients characterized their pain intensity by a visual analog scale (a 
score of zero meant no pain and a score of 10 equaled the worst imaginable pain).2  
Finally, one of the outcomes measured in the Lam et al study was abdominal pain 
severity while on the Mesalazine or the Placebo treatment during the study. For this outcome, 
patients completed 7-day weekly stool diaries for 12 weeks. Patients scored their abdominal pain 
severity between 0 (no symptoms) and 10 (extremely severe symptoms).3 
RESULTS 
 All three studies that are evaluated in this review are randomized controlled trials that 
included an assessment of the satisfactory relief of abdominal pain/IBS symptoms and pain 
intensity. The population included in all three studies were adults over the age of 18. The 
comparisons in two of the studies was a placebo pill,1,3 and one study’s intervention was 
compared to “standard therapy without Mesalazine for 28 days”.2 The study conducted by 
Barbara et al contained dichotomous data that could be used to calculate RBI, ABI, and NNT,1 
while the other two studies included in this review contained continuous data that could not be 
converted, and rather, used p-values to determine the statistical significance between the 
interventions and comparisons.2,3 
 The study conducted by Barbara et al included 180 patients that were aged 18-65 years 
old, and 50 of those participants withdrew from the study. These participants withdrew for 
several reasons, including “consent withdrawal (17 patients), adverse events (14 patients), lost 
during follow-up (8 patients), protocol violation (6 patients), and other reasons (5 patients)”.1 
Compliance of study treatment completion was between 70% and 120%, though the study did 
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not mention how this was measured.1 After patients went through the screening process in order 
to become enrolled in the study, the patients were assigned randomly to the intervention or 
control group (Mesalazine 800 mg PO 3x daily for 12 weeks or Placebo PO 3x daily for 12 
weeks, respectively). 88 patients were randomized to Mesalazine, while 92 were randomized to 
the Placebo group. The study’s inclusion and exclusion criteria can be found in Table 1. The 
primary efficacy endpoint in this study was satisfactory relief of abdominal pain/discomfort for 
at least half of the weeks of the treatment period, and this was measured by using a binary scale 
based on the patients’ answers to the following weekly question: “Did you have satisfactory 
relief of your abdominal discomfort or pain during the last week?”.1 The patients were classified 
as responders if they reported an affirmative answer in at least 50% of weeks over a 3-month 
treatment period (50% rule).1 Analysis was performed by intention-to-treat.  
The data from the study was considered dichotomous data. It was found that 68.6% of the 
patients in the Mesalazine group were responders, while 67.4% of Placebo group patients were 
responders.1 The relative benefit increase (RBI) was found to be 0.018, or 1.8%, and the absolute 
benefit increase (ABI) was found to be 0.012, or 1.2%. This showed that the number needed to 
treat (NNT) was 84, therefore, 84 patients needed to be treated with Mesalazine in order to 
achieve one positive outcome from the treatment. These evaluations are highlighted in Table 2. 
The study highlighted several adverse and serious adverse events with treatment during the 
study, where the Placebo group patients featured zero serious adverse events, while the 
Mesalazine group patients featured four serious adverse events (two cases of gastroenteritis, one 
case of ischemic colitis, and one case of breast cancer).1 The placebo group featured 38 adverse 
events (such as URIs, diarrhea, headaches, nausea, and vomiting), while the Mesalazine group 
featured 31 adverse events.1  
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Table 2: Results of Satisfactory Relief of Abdominal Pain in Barbara et al1 
RBI ABI NNT 
0.018 0.012 84 
 
 The study conducted by Dorofeyev et al included 360 patients from the ages of 18-65 
years old. Zero patients withdrew from the study, which shows that all subjects who entered the 
trial were accounted for and attributed to at its conclusion. After patients were screened for 
entrance into the study, patients were randomized into two groups. Every third patient was 
assigned to the treatment group and received Mesalazine 500mg PO QID x 28 days; thus, 120 
patients were in the treatment group. The control group contained the remaining 240 patients, 
and these participants received “standard treatment without mesalazine”.2 The standard treatment 
included Loperamide (2-4mg PO PRN) for diarrhea, Plantago ovata 3.25 g BID or lactulose 
syrup 15-20 mL BID for constipation, Mebeverine 400 mg QD for abdominal pain, or 
Simethicon x 3-5 days for meteorism.2 The study’s inclusion and exclusion criteria can be found 
in Table 1. The outcome from this study that is being addressed is abdominal pain intensity. 
Before and after treatment, patients characterized their pain intensity by a visual analog scale (0 
= no pain and 10 = worst imaginable pain).2 Analysis was performed by intention to treat (ITT).  
The data from this study was considered to be continuous data. For the intention to treat 
population, the baseline mean pain intensity score for all patients (patients in both the 
intervention and control groups) together = 7.6 (n = 360). For the intention to treat population for 
the control group, mean pain intensity score after the study was 3.8 (n = 240). For the intention 
to treat population for the Mesalazine treatment group, the mean pain intensity score after the 
study was 1.4 (n = 120).2 Table 3 lists the mean pain intensity scores for the intention to treat 
population. Significance of differences of mean values between the mesalazine and standard 
treatment groups was determined by Student’s t-test. The article did not specifically state the p-
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value for the difference in mean abdominal pain intensity score after treatment for the intention 
to treat population, but did indicate that the difference between the two groups in the intention-
to-treat population was statistically significant, with a p-value < 0.05. The percent mean change 
from baseline was not calculated by the experimenters, and could not be interpreted, due to the 
study only listing the baseline mean pain intensity score for all participants together, and then 
separating the final pain intensity score based on intervention or control group. Study compliance 
regarding patient adherence was not discussed in the study. The study did assess safety and 
adverse events with regards to its study participants. Thirteen patients that were in the 
Mesalazine group reported an adverse event and twenty-nine patients that were in the standard 
treatment group reported adverse events, which consisted of “headaches, nasopharyngitis, and 
flu-like infections”.2 There were no significant adverse events reported in the study. 
Table 3: Mean Abdominal Pain Intensity Scores for ITT Population in Dorofeyev et al2 
 Baseline Mean Pain 
Intensity Score for all 
Study Participants 
Mean Pain Intensity Score 
Post-Treatment for 
Mesalazine Group 
Mean Pain Intensity Score 
Post-Treatment for 
Standard Treatment Group 
Pain Intensity Score (1-
10) 
7.6 1.4 2.8 
 
 The study conducted by Lam et al included 136 participants from the ages of 18-75 years 
old. Inclusion and exclusion criteria is listed in Table 1. These 136 patients were randomly 
allocated to either the Mesalazine or Placebo treatment group, where 2 grams Mesalazine PO 
twice daily for 3 months was used for the intervention, and 2 g placebo PO once daily for one 
week, and if tolerated, then 2 g twice a day for 11 weeks, was used for the control group.3 In the 
Mesalazine group, two patients withdrew consent, one was lost to follow-up, and eight had an 
adverse event, so only 57 patients were included in the ITT analysis.3 For the control group, two 
patients withdrew consent, one was lost to follow up, one had an incomplete diary, and six had 
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adverse events, so only 58 patients were included in the ITT analysis. The outcome that is being 
addressed from this study is daily mean abdominal pain score, where participants used a daily 
stool diary and rated abdominal pain daily on a score from 0 (no symptoms) to 10 (extremely 
severe abdominal pain).3 
 The baseline daily mean abdominal pain score for the Mesalazine group, that included the 
patients that later withdrew from the study, was 4.1, with a standard deviation (SD) of 2.2. The 
baseline daily mean abdominal pain score for the placebo group, that included the patients that 
later withdrew from the study, was 3.6, with a SD of 2.0. At the end of treatment (EOT), the 
average abdominal pain score for the Mesalazine group was 2.8, with a SD of 2.1. The average 
abdominal pain score for the placebo group at EOT was 2.2, with a SD of 2.1. The between 
group comparison at EOT, with a 95% CI, was 0.07, and when analyzed according to the 
Consolidated Standards of Reporting Trials guidance, using Stata V.13. showed a p-value of 
0.83,3 which is not statistically significant (p< 0.05 is considered statistically significant). These 
values can be found listed in Table 4. Compliance was measured in the study as taking greater 
than or equal to 75% of the medication throughout the twelve weeks of the study. The amount of 
medication taken was determined by the number of pills remaining the medication boxes 
returned at EOT. Compliance with medication during the whole twelve weeks of the study for 
the ITT population was 71% for Mesalazine and 72% for the placebo groups.3 Adverse events 
were recorded during the study and all patients that reported these adverse events were not 
included in the ITT population, which included symptoms such as bloating, chest pain, dizziness, 
rash, and others. Two patients from the Mesalazine group and three patients from the placebo 
group reported exacerbation of IBS symptoms (worsening abdominal pain or diarrhea).3 The 
only major adverse event was that one patient in the Mesalazine group was found to have breast 
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cancer. Overall, there were eight adverse events in the Mesalazine group, and six adverse events 
in the placebo group.3  
Table 4: Average Abdominal Pain Score with Standard Deviation in Lam et al study3 
 Mesalazine Baseline Placebo Baseline Mesalazine EOT Placebo EOT 
Mean Abdominal 
Pain Score 
4.1 3.6 2.8 2.2 
Standard Deviation 2.2 2.0 2.1 2.1 
 
DISCUSSION 
 The three randomized controlled trials discussed in this study were created to investigate 
whether Mesalazine is an effective treatment for relieving the symptoms, primarily abdominal 
pain, in IBS patients. The results from the studies show conflicting evidence, as Barbara et al and 
Lam et al show no statistically significant difference in the relief of abdominal pain/pain 
intensity between Mesalazine and Placebo treatment, while Dorofeyev et al did show a 
statistically significant difference between Mesalazine and standard treatment for IBS patients. 
While this review is primarily reviewing the effect Mesalazine has on the relief of the symptom 
of abdominal pain, there are many other symptoms of IBS, such as bloating and stool 
frequency,1,3 as well as biopsy samples, that the studies also investigated that can be reviewed 
and analyzed. 
 There were several limitations to these studies. For instance, with the pain severity scales 
used in Dorofeyev et al and Lam et al, these were a subjective measure, as different people have 
different pain tolerances and these results of abdominal pain intensity post treatment could not be 
considered as consistent across all patients. In addition, the Dorofeyev et al study did not 
compare baseline mean pain intensity scores separately for Mesalazine and standard treatment; 
thus, the analysis of the percent mean change from baseline cannot accurately be calculated. 
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While the experimenters in this study did record a statistically significant difference in the 
intervention and control group treatments post-treatment, they did not compare the post-
treatment to the baseline. The Dorofeyev article also did not use a standard placebo for the 
control, and only conducted their study for four weeks. 
 The primary use of Mesalazine and other aminosalicylates is for the treatment of 
inflammatory bowel disease. It has been in use for more than 30 years in the treatment of IBD, 
more specifically now in Ulcerative Colitis treatment, and has the best safety profile of all IBD 
drugs.10 Mesalazine side effects are minor in nature and include headache, nausea, and diarrhea. 
More serious side effects include pancreatitis and renal dysfunction, but are rarer, and warrant 
further investigation.10 
CONCLUSION 
 This review shows inconsistent and inconclusive evidence for the use of Mesalazine in 
improving the symptoms in IBS patients, namely abdominal pain. Two studies showed no 
statistically significant evidence between Mesalazine and placebo, while one study suggested 
there was a significant difference in the abdominal pain intensity between Mesalazine and 
standard treatment. According to these results, further studies are warranted to investigate 
whether Mesalazine would be an effective treatment for IBS patients, and further studies should 
be done to account for if Mesalazine has an effect on improving the symptoms of IBS over a 
longer period of time or to study the effects of the drug on different symptoms of IBS.
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